Thrombin activatable fibrinolysis inhibitor (TAFI) Cat.#
This data sheet is provided for information only. After adding the product to the cart by clicking the button below you will see if there is a volume discount available.
Plasma samples from donors were tested and found negative for HbsAg, HIV-1 and HIV-2 antibodies, HCV, and syphilis
Immunological and mass TAFI standard.
TAFI (synonyms: procarboxypeptidase B, carboxypeptidase U, carboxypeptidase R) is a plasma protein circulating as a zymogen. Being activated by thrombin-thrombomodulin complex during blood coagulation, it exerts carboxypeptidase activity. It splits out C-terminal lysine from fibrin and prevents fibrin lysis by plasmin. TAFI is considered as a risk factor for cardiovascular diseases.
Purity > 90 %
(SDS-PAGE). Protein concentration determined by the Lowry procedure.
Frozen in 10mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl.
-20 °C (-15 … -30 °C allowed)
|Material safety note:||
This product is sold for research use only. Standard Laboratory Practices should be followed when handling this material.
Download datasheet as a PDF file below
- 8TA1_TAFI.pdf (pdf)